Updates are available Correction dated 2022-02-07
Click to view Correction: https://doi.org/10.1038/s41586-021-04299-0
-
Authors
Diwanji, Devan
Trenker, Raphael http://orcid.org/0000-0003-1748-0517
Thaker, Tarjani M.
Wang, Feng
Agard, David A. http://orcid.org/0000-0003-3512-695X
Verba, Kliment A. http://orcid.org/0000-0002-2238-8590
Jura, Natalia http://orcid.org/0000-0001-5129-641X
- License Information
-
More Information
Article History
Received: 13 April 2021
Accepted: 29 September 2021
First Online: 10 November 2021
Change Date: 7 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-04299-0
Competing interests
: N.J. is a member of the Scientific Advisory Board and a shareholder of Turning Point Therapeutics, SUDO Biosciences and Type6 Therapeutics. The Jura laboratory has received sponsored research support from Genentech. The other authors declare no competing interests.
